690 related articles for article (PubMed ID: 8740587)
41. Differential regulation of matrix metalloproteinases and their inhibitors in human glomerular epithelial cells in vitro.
Martin J; Steadman R; Knowlden J; Williams J; Davies M
J Am Soc Nephrol; 1998 Sep; 9(9):1629-37. PubMed ID: 9727371
[TBL] [Abstract][Full Text] [Related]
42. Chondrocyte cultures express matrix metalloproteinase mRNA and immunoreactive protein; stromelysin-1 and 72 kDa gelatinase are localized in extracellular matrix vesicles.
Schmitz JP; Dean DD; Schwartz Z; Cochran DL; Grant GM; Klebe RJ; Nakaya H; Boyan BD
J Cell Biochem; 1996 Jun; 61(3):375-91. PubMed ID: 8761942
[TBL] [Abstract][Full Text] [Related]
43. Increased expression of matrix metalloproteinases and matrix degrading activity in vulnerable regions of human atherosclerotic plaques.
Galis ZS; Sukhova GK; Lark MW; Libby P
J Clin Invest; 1994 Dec; 94(6):2493-503. PubMed ID: 7989608
[TBL] [Abstract][Full Text] [Related]
44. Collagenases and tissue inhibitors of metalloproteinases: a functional balance in tissue degradation.
Reynolds JJ
Oral Dis; 1996 Mar; 2(1):70-6. PubMed ID: 8957940
[TBL] [Abstract][Full Text] [Related]
45. Matrix metalloproteinases and their inhibitors in gastric cancer.
Murray GI; Duncan ME; Arbuckle E; Melvin WT; Fothergill JE
Gut; 1998 Dec; 43(6):791-7. PubMed ID: 9824606
[TBL] [Abstract][Full Text] [Related]
46. The distribution of matrix metalloproteinases and tissue inhibitor of metalloproteinases in colorectal cancer.
Gallegos NC; Smales C; Savage FJ; Hembry RM; Boulos PB
Surg Oncol; 1995 Feb; 4(1):21-9. PubMed ID: 7780609
[TBL] [Abstract][Full Text] [Related]
47. Expression of matrix metalloproteinases and tissue inhibitor of metalloproteinases in head and neck squamous cell carcinoma.
Charous SJ; Stricklin GP; Nanney LB; Netterville JL; Burkey BB
Ann Otol Rhinol Laryngol; 1997 Apr; 106(4):271-8. PubMed ID: 9109715
[TBL] [Abstract][Full Text] [Related]
48. Transcriptional suppression of matrix metalloproteinase-2 gene expression in human astroglioma cells by TNF-alpha and IFN-gamma.
Qin H; Moellinger JD; Wells A; Windsor LJ; Sun Y; Benveniste EN
J Immunol; 1998 Dec; 161(12):6664-73. PubMed ID: 9862695
[TBL] [Abstract][Full Text] [Related]
49. IL-10 blocks collagen IV invasion by "invasion stimulating factor" activated PC-3 ML cells: upregulation of TIMP-1 expression.
Stearns ME; Wang M; Stearns M
Oncol Res; 1995; 7(3-4):157-63. PubMed ID: 8555649
[TBL] [Abstract][Full Text] [Related]
50. Human hepatocellular carcinoma (HCC) cells require both alpha3beta1 integrin and matrix metalloproteinases activity for migration and invasion.
Giannelli G; Bergamini C; Fransvea E; Marinosci F; Quaranta V; Antonaci S
Lab Invest; 2001 Apr; 81(4):613-27. PubMed ID: 11304581
[TBL] [Abstract][Full Text] [Related]
51. 92K-GL (MMP-9) and 72K-GL (MMP-2) are produced in vivo by human oral squamous cell carcinomas and can enhance FIB-CL (MMP-1) activity in vitro.
Pickett KL; Harber GJ; DeCarlo AA; Louis P; Shaneyfelt S; Windsor LJ; Bodden MK
J Dent Res; 1999 Jul; 78(7):1354-61. PubMed ID: 10403463
[TBL] [Abstract][Full Text] [Related]
52. Association of MMP-2 activation potential with metastatic progression in human breast cancer cell lines independent of MMP-2 production.
Azzam HS; Arand G; Lippman ME; Thompson EW
J Natl Cancer Inst; 1993 Nov; 85(21):1758-64. PubMed ID: 8411260
[TBL] [Abstract][Full Text] [Related]
53. Activation of gelatinase A (72-kDa type IV collagenase) induced by monensin in normal human fibroblasts.
Li L; Akers K; Eisen AZ; Seltzer JL
Exp Cell Res; 1997 May; 232(2):322-30. PubMed ID: 9168808
[TBL] [Abstract][Full Text] [Related]
54. Presence of active gelatinases in endometrial carcinoma and correlation of matrix metalloproteinase expression with increasing tumor grade and invasion.
Di Nezza LA; Misajon A; Zhang J; Jobling T; Quinn MA; Ostör AG; Nie G; Lopata A; Salamonsen LA
Cancer; 2002 Mar; 94(5):1466-75. PubMed ID: 11920503
[TBL] [Abstract][Full Text] [Related]
55. 72-kD (MMP-2) and 92-kD (MMP-9) type IV collagenase production and activity in different histologic types of lung cancer cells.
González-Avila G; Iturria C; Vadillo F; Terán L; Selman M; Pérez-Tamayo R
Pathobiology; 1998; 66(1):5-16. PubMed ID: 9577961
[TBL] [Abstract][Full Text] [Related]
56. TIMP-2 mediates cell surface binding of MMP-2.
Corcoran ML; Emmert-Buck MR; McClanahan JL; Pelina-Parker M; Stetler-Stevenson WG
Adv Exp Med Biol; 1996; 389():295-304. PubMed ID: 8861023
[TBL] [Abstract][Full Text] [Related]
57. Gelatinase-A (MMP-2), gelatinase-B (MMP-9) and membrane type matrix metalloproteinase-1 (MT1-MMP) are involved in different aspects of the pathophysiology of malignant gliomas.
Forsyth PA; Wong H; Laing TD; Rewcastle NB; Morris DG; Muzik H; Leco KJ; Johnston RN; Brasher PM; Sutherland G; Edwards DR
Br J Cancer; 1999 Apr; 79(11-12):1828-35. PubMed ID: 10206300
[TBL] [Abstract][Full Text] [Related]
58. Matrix metalloproteinase-2 is an interstitial collagenase. Inhibitor-free enzyme catalyzes the cleavage of collagen fibrils and soluble native type I collagen generating the specific 3/4- and 1/4-length fragments.
Aimes RT; Quigley JP
J Biol Chem; 1995 Mar; 270(11):5872-6. PubMed ID: 7890717
[TBL] [Abstract][Full Text] [Related]
59. Expression of matrix metalloproteinases and their tissue inhibitors in human brain tumors.
Lampert K; Machein U; Machein MR; Conca W; Peter HH; Volk B
Am J Pathol; 1998 Aug; 153(2):429-37. PubMed ID: 9708803
[TBL] [Abstract][Full Text] [Related]
60. Expression and function of matrix metalloproteinases and their inhibitors at the maternal-embryonic boundary during mouse embryo implantation.
Alexander CM; Hansell EJ; Behrendtsen O; Flannery ML; Kishnani NS; Hawkes SP; Werb Z
Development; 1996 Jun; 122(6):1723-36. PubMed ID: 8674412
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
